Extravasation Injury (Chemotherapy)

1. Executive Overview: Understanding Chemotherapy Extravasation

Extravasation injury refers to the accidental infiltration of vesicant or irritant chemotherapeutic agents into the subcutaneous or subdermal tissues surrounding an intravenous (IV) access site. As a complication of oncological therapy, it represents a significant clinical challenge that requires immediate recognition and intervention to prevent severe morbidity.

In the context of plastic and reconstructive surgery, we classify these injuries based on their potential for tissue necrosis. Vesicant agents (such as anthracyclines like doxorubicin or epirubicin) are capable of causing profound tissue destruction, leading to ulceration, necrosis, and potential exposure of underlying tendons, nerves, or bone. Conversely, irritants may cause inflammatory reactions, including phlebitis and pain, but generally lack the same destructive potential as true vesicants.

The ICD-10 code T80.818A (Extravasation of other specified agent, initial encounter) is the formal diagnostic classification used to track these events. Early surgical consultation is the gold standard for managing high-risk extravasations to minimize the need for extensive debridement and complex reconstructive procedures.

2. Pathophysiology, Etiology, and Risk Factors

Pathophysiology

The mechanism of injury is multifactorial, depending primarily on the chemical properties of the drug. Chemotherapeutic agents induce injury through:
* Direct Cytotoxicity: Agents like DNA-binding drugs (anthracyclines) bind to the DNA of healthy local cells, causing cell death. Even if the drug is eventually cleared, the remaining drug molecules can be re-ingested by neighboring cells, leading to a "domino effect" of necrosis.
* Osmotic Damage: Hypertonic solutions cause cellular dehydration and inflammatory cascades.
* pH Extremes: Extremes in pH disrupt the cellular membrane integrity.

Etiology and Risk Factors

The occurrence of extravasation is rarely due to a single cause. Instead, it is often a confluence of patient-related and procedural factors:

3. Signs, Symptoms, and Clinical Presentation

Clinical presentation typically evolves over hours to weeks. The initial phase is often deceptive, which is why clinical suspicion must remain high.

• Immediate Phase (Minutes to Hours): Patients may report burning sensations, stinging, or pain at the site. Erythema, edema, and induration are common.
• Intermediate Phase (Days 1–7): The site may appear to improve temporarily, but then progresses to darkening of the skin, blistering (bullae), and the formation of a hard, indurated plaque.
• Late Phase (Weeks): Development of full-thickness tissue necrosis, ulceration with a necrotic base, and secondary infection.

Clinical Staging Table

4. Standard Diagnostic Evaluation & Workup

The diagnosis of extravasation is primarily clinical. However, in cases of uncertainty or severe injury, a structured workup is essential.

Diagnostic Criteria

1. Clinical History: Recent administration of vesicant chemotherapy.
2. Physical Examination: Assessment of the area of infiltration (size, depth, presence of necrosis).
3. Neurovascular Assessment: Checking distal pulses, capillary refill, and sensation (to rule out compartment syndrome).

Diagnostic Investigations

• Ultrasound (High-Frequency): The gold standard for assessing the depth of the infiltrate and determining if the drug has reached the deep fascial plane.
• Punch Biopsy: Rarely indicated, but may be used in chronic, non-healing wounds to rule out malignant infiltration or secondary infection.
• MRI/CT Scan: Utilized if there is suspicion of deep tissue involvement, such as necrosis tracking along muscle compartments or involvement of underlying bone.

5. Therapeutic Interventions

Management is time-sensitive. The primary objective is to neutralize the agent and promote tissue viability.

Pharmacotherapy (The "Antidote" Approach)

Specific agents have targeted antidotes:
* Dexrazoxane: The FDA-approved antidote for anthracycline extravasation. It acts as a topoisomerase II inhibitor, preventing the drug from causing DNA damage. It is most effective when administered within 6 hours of the incident.
* Hyaluronidase: Used for vinca alkaloids (e.g., vincristine) to facilitate the spread and absorption of the drug into the systemic circulation, thereby reducing local concentration.

Surgical Interventions

When conservative management fails or if the injury is high-grade (Stage 3), plastic surgery intervention is mandatory:
1. Surgical Debridement: The gold standard for necrotic tissue removal. We perform serial debridements to ensure all devitalized tissue is excised.
2. Negative Pressure Wound Therapy (NPWT): Used to manage the wound bed, reduce edema, and prepare the site for secondary closure.
3. Reconstructive Procedures: Once the wound is clean, we utilize skin grafts (split-thickness or full-thickness) or local/free flaps to achieve definitive coverage, especially over vital structures like tendons or nerves.

Lifestyle and Supportive Care

• Elevation: Keep the affected limb elevated to minimize lymphatic congestion.
• Wound Care: Sterile dressings and monitoring for signs of cellulitis.
• Pain Management: Multimodal analgesia to improve patient quality of life.

6. Frequently Asked Questions (FAQ)

1. Is it normal to have pain after chemotherapy infusion?
While some mild discomfort is possible, severe or worsening pain at the infusion site is a red flag for extravasation and must be reported to your oncologist immediately.

2. What is the most dangerous type of chemotherapy for extravasation?
Anthracyclines (e.g., Doxorubicin) are notorious for causing severe, progressive tissue necrosis and are considered the most dangerous in terms of extravasation injury.

3. How quickly must I seek treatment after noticing an extravasation?
Immediate action is required. Ideally, intervention should occur within 1–6 hours to utilize antidotes like Dexrazoxane effectively.

4. Will I need surgery?
Surgery is not always necessary. If detected early and managed appropriately, many extravasations heal with conservative care. Surgery is reserved for cases of necrosis or deep tissue damage.

5. How does a plastic surgeon help with these injuries?
Plastic surgeons specialize in wound healing and complex reconstruction. We perform surgical debridement and reconstructive procedures (flaps/grafts) to restore function and integrity to the affected area.

6. Can extravasation cause permanent damage?
Yes, if left untreated or if the injury is severe, it can result in permanent scarring, loss of range of motion, or nerve damage requiring long-term rehabilitation.

7. Is an ultrasound necessary for every extravasation?
Not necessarily. Ultrasound is used when the extent of the infiltration is unclear or if there is a suspicion that the vesicant has reached deep tissue planes.

8. What is the role of Dexrazoxane?
Dexrazoxane is a protective agent that significantly reduces the risk of tissue necrosis when given after an anthracycline extravasation.

9. Can I apply ice to the site?
The use of ice is controversial and depends on the specific drug. For some agents, it may worsen the injury by increasing the concentration of the drug. Always consult your oncology nurse before applying cold or heat.

10. What is the prognosis for full-thickness necrosis?
With aggressive surgical management and modern reconstructive techniques, the prognosis for wound closure is generally good, though recovery can be a lengthy process requiring physical therapy.